Prediction of pre-eclampsia and its subtypes in high-risk cohort: hyperglycosylated human chorionic gonadotropin in multivariate models

What Was Tested

The paper reports a study of hCG (human chorionic gonadotropin), published as a randomized controlled trial.

The researchers wanted to evaluate the performance of clinical risk factors, mean arterial pressure (MAP), %hCG-h, hCGβ, pregnancy-associated plasma protein A (PAPP-A), placental growth factor (PlGF) and mean pulsatility index of the uterine artery (Uta-PI) in the first trimester in predicting pre-eclampsia (PE) and its subtypes early-onset, late-onset, severe and non-severe PE in a high-risk cohort.

Why It Was Studied

International Standard Randomised Controlled Trial number ISRCTN14030412 , Date of registration 6/09/2007, retrospectively registered.

Who Took Part

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

Multivariate logistic regression was used to construct the prediction models.

The first model included background variables and MAP.

Additionally, biomarkers were included in the second model and mean Uta-PI was included in the third model.

The area under the curve (AUC) was determined for all models.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Biomarkers, Blood Pressure Determination, Chorionic Gonadotropin, Chorionic Gonadotropin, beta Subunit, Human, Placenta Growth Factor and Pre-Eclampsia.

Author keywords: Early-onset pre-eclampsia, Hyperglycosylated human chorionic gonadotropin, Late-onset pre-eclampsia, Placental growth factor, Pregnancy associated plasma protein a and Screening.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (BMC pregnancy and childbirth), a journal based in England.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.